Pivotal Phase 3 ARISE trial evaluating solengepras as an adjunctive treatment in Parkinson’s disease is underway and actively enrolling patients BOSTON, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Cerevance, a ...

Preliminary Activity Analysis In the 15 efficacy-evaluable patients in the 120 mg cohort, the majority of which received an effective dose of 80 mg QD, enozertinib demonstrated strong systemic and CNS ...

KALA BIO, Inc. (NASDAQ:KALA) (“KALA” or the “Company”), today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase of ...

Company to host video conference call and webcast at 8:00 a.m. ET on Monday, December 8, 2025 ...

Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel neuroplastogen-derived therapeutics ...

Pheton Holdings Ltd (NASDAQ: PTHL) (“Pheton” or the “Company”), a healthcare solution provider specializing in treatment planning systems for brachytherapy and other related products and services, ...

The Company intends to use the net proceeds from the Offering primarily for development activities, including the completion of its pivotal trial, and preparation of the PMA submission for GerlinC, ...

Washington, DC, Dec. 05, 2025 (GLOBE NEWSWIRE) -- First Lady Melania Trump visited Children’s National Hospital today to celebrate the holiday season with patients, families and staff, renewing a ...

About Meihua International Medical Technologies Co., Ltd.

Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company and the global leader in precision targeting of PRAME, announced today that it has agreed to sell ...

A recent setback due to unexpected safety concern from a phase 2 study to evaluate a STAT3 inhibitor in IPF patients refreshed an old debate regarding the feasibility to develop therapeutics targeting ...

This data is from SOTA-P-CARDIA, a prospective, randomized, double-blind, placebo-controlled trial that exclusively enrolled patients with heart failure with preserved ejection fraction (HFpEF) and ...